These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 34249742)

  • 1. Irradiation-Modulated Murine Brain Microenvironment Enhances GL261-Tumor Growth and Inhibits Anti-PD-L1 Immunotherapy.
    Garbow JR; Johanns TM; Ge X; Engelbach JA; Yuan L; Dahiya S; Tsien CI; Gao F; Rich KM; Ackerman JJH
    Front Oncol; 2021; 11():693146. PubMed ID: 34249742
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Cai Z; Liu R; Chan C; Lu Y; Winnik MA; Cescon DW; Reilly RM
    Mol Pharm; 2022 Nov; 19(11):4199-4211. PubMed ID: 36287201
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas.
    Zeng J; See AP; Phallen J; Jackson CM; Belcaid Z; Ruzevick J; Durham N; Meyer C; Harris TJ; Albesiano E; Pradilla G; Ford E; Wong J; Hammers HJ; Mathios D; Tyler B; Brem H; Tran PT; Pardoll D; Drake CG; Lim M
    Int J Radiat Oncol Biol Phys; 2013 Jun; 86(2):343-9. PubMed ID: 23462419
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Late Effects of Radiation Prime the Brain Microenvironment for Accelerated Tumor Growth.
    Duan C; Yang R; Yuan L; Engelbach JA; Tsien CI; Rich KM; Dahiya SM; Johanns TM; Ackerman JJH; Garbow JR
    Int J Radiat Oncol Biol Phys; 2019 Jan; 103(1):190-194. PubMed ID: 30171879
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunovirotherapy with measles virus strains in combination with anti-PD-1 antibody blockade enhances antitumor activity in glioblastoma treatment.
    Hardcastle J; Mills L; Malo CS; Jin F; Kurokawa C; Geekiyanage H; Schroeder M; Sarkaria J; Johnson AJ; Galanis E
    Neuro Oncol; 2017 Apr; 19(4):493-502. PubMed ID: 27663389
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radiation therapy enhances systemic antitumor efficacy in PD-L1 therapy regardless of sequence of radiation in murine osteosarcoma.
    Katsuki S; Takahashi Y; Tamari K; Minami K; Takenaka W; Ibuki Y; Yamamoto J; Tatekawa S; Hayashi K; Seo Y; Isohashi F; Ogawa K; Koizumi M
    PLoS One; 2022; 17(7):e0271205. PubMed ID: 35816501
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation of MR-Based Metabolomics and Molecular Profiling in the Tumor Microenvironment of Temozolomide-Treated Orthotopic GL261 Glioblastoma in Mice.
    Zhao K; Calero-Pérez P; Bopp MHA; Möschl V; Pagenstecher A; Mulero-Acevedo M; Vázquez M; Barcia C; Arús C; Nimsky C; Rusch T; Bartsch JW; Candiota AP
    Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-VEGF antibodies mitigate the development of radiation necrosis in mouse brain.
    Jiang X; Engelbach JA; Yuan L; Cates J; Gao F; Drzymala RE; Hallahan DE; Rich KM; Schmidt RE; Ackerman JJ; Garbow JR
    Clin Cancer Res; 2014 May; 20(10):2695-702. PubMed ID: 24647570
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Triple combination immunotherapy with GVAX, anti-PD-1 monoclonal antibody, and agonist anti-OX40 monoclonal antibody is highly effective against murine intracranial glioma.
    Jahan N; Talat H; Alonso A; Saha D; Curry WT
    Oncoimmunology; 2019; 8(5):e1577108. PubMed ID: 31069135
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-PD-L1 antibody direct activation of macrophages contributes to a radiation-induced abscopal response in glioblastoma.
    Ene CI; Kreuser SA; Jung M; Zhang H; Arora S; White Moyes K; Szulzewsky F; Barber J; Cimino PJ; Wirsching HG; Patel A; Kong P; Woodiwiss TR; Durfy SJ; Houghton AM; Pierce RH; Parney IF; Crane CA; Holland EC
    Neuro Oncol; 2020 May; 22(5):639-651. PubMed ID: 31793634
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Tumor Microenvironment Regulates Sensitivity of Murine Lung Tumors to PD-1/PD-L1 Antibody Blockade.
    Li HY; McSharry M; Bullock B; Nguyen TT; Kwak J; Poczobutt JM; Sippel TR; Heasley LE; Weiser-Evans MC; Clambey ET; Nemenoff RA
    Cancer Immunol Res; 2017 Sep; 5(9):767-777. PubMed ID: 28819064
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Infiltration of CD163-positive macrophages in glioma tissues after treatment with anti-PD-L1 antibody and role of PI3Kγ inhibitor as a combination therapy with anti-PD-L1 antibody in in vivo model using temozolomide-resistant murine glioma-initiating cells.
    Miyazaki T; Ishikawa E; Matsuda M; Sugii N; Kohzuki H; Akutsu H; Sakamoto N; Takano S; Matsumura A
    Brain Tumor Pathol; 2020 Apr; 37(2):41-49. PubMed ID: 31980975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Positron Emission Tomography Imaging of Functional Transforming Growth Factor β (TGFβ) Activity and Benefit of TGFβ Inhibition in Irradiated Intracranial Tumors.
    Gonzalez-Junca A; Reiners O; Borrero-Garcia LD; Beckford-Vera D; Lazar AA; Chou W; Braunstein S; VanBrocklin H; Franc BL; Barcellos-Hoff MH
    Int J Radiat Oncol Biol Phys; 2021 Feb; 109(2):527-539. PubMed ID: 33007434
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A tumor-targeting nanomedicine carrying the p53 gene crosses the blood-brain barrier and enhances anti-PD-1 immunotherapy in mouse models of glioblastoma.
    Kim SS; Harford JB; Moghe M; Slaughter T; Doherty C; Chang EH
    Int J Cancer; 2019 Nov; 145(9):2535-2546. PubMed ID: 31241175
    [TBL] [Abstract][Full Text] [Related]  

  • 15. STI571 (Gleevec) improves tumor growth delay and survival in irradiated mouse models of glioblastoma.
    Geng L; Shinohara ET; Kim D; Tan J; Osusky K; Shyr Y; Hallahan DE
    Int J Radiat Oncol Biol Phys; 2006 Jan; 64(1):263-71. PubMed ID: 16274936
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stable luciferase expression does not alter immunologic or in vivo growth properties of GL261 murine glioma cells.
    Clark AJ; Safaee M; Oh T; Ivan ME; Parimi V; Hashizume R; Ozawa T; James CD; Bloch O; Parsa AT
    J Transl Med; 2014 Dec; 12():345. PubMed ID: 25464980
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination immunotherapy and radiotherapy causes an abscopal treatment response in a mouse model of castration resistant prostate cancer.
    Dudzinski SO; Cameron BD; Wang J; Rathmell JC; Giorgio TD; Kirschner AN
    J Immunother Cancer; 2019 Aug; 7(1):218. PubMed ID: 31412954
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical immunoPET/CT imaging using Zr-89-labeled anti-PD-L1 monoclonal antibody for assessing radiation-induced PD-L1 upregulation in head and neck cancer and melanoma.
    Kikuchi M; Clump DA; Srivastava RM; Sun L; Zeng D; Diaz-Perez JA; Anderson CJ; Edwards WB; Ferris RL
    Oncoimmunology; 2017; 6(7):e1329071. PubMed ID: 28811971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 20. Inhibitors of HIF-1α and CXCR4 Mitigate the Development of Radiation Necrosis in Mouse Brain.
    Yang R; Duan C; Yuan L; Engelbach JA; Tsien CI; Beeman SC; Perez-Torres CJ; Ge X; Rich KM; Ackerman JJH; Garbow JR
    Int J Radiat Oncol Biol Phys; 2018 Mar; 100(4):1016-1025. PubMed ID: 29485043
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.